Clinical Trials Logo

ALK-positive Advanced NSCLC clinical trials

View clinical trials related to ALK-positive Advanced NSCLC.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02511184 Terminated - Clinical trials for ALK-positive Advanced NSCLC

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Start date: October 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the safety, tolerability, and anti-tumor activity of the combination.